In this Review:
IBD genetic risk variants influence gut microbiome
A potential key PSC modifier gene
AZA dose reduction in IBD combination therapy
ADA ± AZA in Crohn’s disease
6MP beneficial in postoperative management of CD
TNFi therapy complicates ileocolonic CD surgery
Risk factors for colorectal neoplasia in UC
Cx601 (eASC) for complex perianal fistulas in CD
Ustekinumab induces clinical response/remission in refractory CD
anti-IL-6 antibody in refractory CD
Please login below to download this issue (PDF)